AbbVie to Acquire Apogee for $10.9 Billion

AbbVie has announced its acquisition of Apogee, an immunology-focused pharmaceutical company, in a deal valued at $10.9 billion. This strategic move is part of AbbVie's goal to strengthen its immunology portfolio and enhance growth potential. The acquisition aims to offer new treatment options that complement AbbVie's existing drug pipeline. The purchase will integrate Apogee's developmental immunology drugs and technologies into AbbVie, enabling the company to target a broader product range, particularly in areas such as autoimmune diseases. The deal is expected to create value for shareholders of both companies. Financially, the $10.9 billion acquisition will be funded through AbbVie's cash and debt instruments. The company anticipates that this investment will boost long-term profitability and solidify its position in the immunology market. The transaction is expected to close in 2024, pending regulatory approvals. This is not investment advice.